# Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

> **NCT00612742** · PHASE3 · COMPLETED · sponsor: **BioSante Pharmaceuticals** · enrollment: 3656 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** testosterone gel
- **DRUG:** placebo gel

## Key facts

- **NCT ID:** NCT00612742
- **Lead sponsor:** BioSante Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 3656 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612742, "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00612742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*